ReviewJournal of clinical medicine2022
Management of High-Risk Pulmonary Embolism: What Is the Place of Extracorporeal Membrane Oxygenation?
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Global hotspot and trend of extracorporeal membrane oxygenation for pulmonary embolism.Frontiers in medicine · 2025Pooled it
- The use of Veno-arterial Extracorporeal Membrane Oxygenation (VA-ECMO) for Acute High Risk Pulmonary Embolism: A Systematic Review.Current cardiology reviews · 2025Pooled it
- Advancements in Pulmonary Embolism Management: Current Approaches and Future Directions.Reviews in cardiovascular medicine · 2025Review
- [Extracorporeal cardiopulmonary resuscitation in postpartum pulmonary embolism].Die Anaesthesiologie · 2025Article
- Management of high-risk acute pulmonary embolism: an emulated target trial analysis.Intensive care medicine · 2025Observational
- Hospital Zambrano Hellion pulmonary embolism response team: PERT-PREVENTION.Archivos de cardiologia de Mexico · 2025Article
- Severe Traumatic Brain Injury and Pulmonary Embolism: Risks, Prevention, Diagnosis and Management.Journal of clinical medicine · 2024Review
- A Brief Historical Perspective on Pulmonary Embolism.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024Review
- Role of Extracorporeal Membrane Oxygenation in the Treatment of Massive Pulmonary Embolism.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024Review
- Veno-venous or veno-arterial extracorporeal membrane oxygenation support for massive pulmonary embolism: a case report.AME case reports · 2024Article
- Is Extracorporeal Membrane Oxygenation a Panacea?The Eurasian journal of medicine · 2023Article
- Cardiac arrest secondary to pulmonary embolism treated with extracorporeal cardiopulmonary resuscitation: Six case reports.World journal of clinical cases · 2023Article
- Ventricular interdependence in critically ill patients: from physiology to bedside.Frontiers in physiology · 2023Review
- Hemodynamic and respiratory support in pulmonary embolism: a narrative review.Frontiers in medicine · 2023Review
- Use of Extracorporeal Membrane Oxygenation-Facilitated Large-Bore Catheter Embolectomy in the Treatment of Acute Pulmonary Embolism Complicated by Shock.Texas Heart Institute journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary embolism (PE) is a common disease with an annual incidence rate ranging from 39-115 per 100,000 inhabitants. It is one of the leading causes of cardiovascular mortality in the USA and Europe. While the clinical presentation and severity may vary, it is a life-threatening condition in its most severe form, defined as high-risk or massive PE. Therapeutic options in high-risk PE are limited. Current guidelines recommend the use of systemic thrombolytic therapy as first-line therapy (Level Ib). However, this treatment has important drawbacks including bleeding complications, limited efficacy in patients with recurrent PE or cardiac arrest, and formal contraindications. In this context, the use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) in the management of high-risk PE has increased worldwide in the last decade. Strategies, including VA-ECMO as a stand-alone therapy or as a bridge to alternative reperfusion therapies, are associated with acceptable outcomes, especially if implemented before cardiac arrest. Nonetheless, the level of evidence supporting ECMO and alternative reperfusion therapies is low. The optimal management of high-risk PE patients will remain controversial until the realization of a prospective randomized trial comparing those cited strategies to systemic thrombolysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.